[go: up one dir, main page]

AU5750196A - Gene therapy of hepatocellular carcinoma through cancer-specific gene expression - Google Patents

Gene therapy of hepatocellular carcinoma through cancer-specific gene expression

Info

Publication number
AU5750196A
AU5750196A AU57501/96A AU5750196A AU5750196A AU 5750196 A AU5750196 A AU 5750196A AU 57501/96 A AU57501/96 A AU 57501/96A AU 5750196 A AU5750196 A AU 5750196A AU 5750196 A AU5750196 A AU 5750196A
Authority
AU
Australia
Prior art keywords
cancer
hepatocellular carcinoma
gene expression
gene therapy
specific gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU57501/96A
Other languages
English (en)
Inventor
W. French Anderson
Yawen L Chiang
Paul L Hallenbeck
Shuichi Kaneko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetic Therapy Inc
University of Southern California USC
Original Assignee
University of South Carolina
Genetic Therapy Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of South Carolina, Genetic Therapy Inc filed Critical University of South Carolina
Publication of AU5750196A publication Critical patent/AU5750196A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/70—Vectors containing special elements for cloning, e.g. topoisomerase, adaptor sites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU57501/96A 1995-05-18 1996-05-16 Gene therapy of hepatocellular carcinoma through cancer-specific gene expression Abandoned AU5750196A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44428495A 1995-05-18 1995-05-18
US444284 1995-05-18
PCT/US1996/007001 WO1996036365A1 (fr) 1995-05-18 1996-05-16 Therapie genique de carcinomes hepatocellulaires par expression de genes specifiques du cancer

Publications (1)

Publication Number Publication Date
AU5750196A true AU5750196A (en) 1996-11-29

Family

ID=23764262

Family Applications (1)

Application Number Title Priority Date Filing Date
AU57501/96A Abandoned AU5750196A (en) 1995-05-18 1996-05-16 Gene therapy of hepatocellular carcinoma through cancer-specific gene expression

Country Status (2)

Country Link
AU (1) AU5750196A (fr)
WO (1) WO1996036365A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698443A (en) * 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
GB9906815D0 (en) 1999-03-24 1999-05-19 Isrec Anti-neoplastic viral agents
WO2019020702A1 (fr) 2017-07-26 2019-01-31 Medizinische Universität Wien Thymidine kinase mutante superactive pour utilisation en thérapie anticancéreuse

Also Published As

Publication number Publication date
WO1996036365A1 (fr) 1996-11-21

Similar Documents

Publication Publication Date Title
AU6124996A (en) Certain arylsulfonamido-substituted hydroxamic acids for the treatment of certain tumors
AU6614696A (en) Inhibition of gene expression
AU3225897A (en) Regulation of gene expression
AU9028798A (en) Method of improving drug treatment
AU3972893A (en) Gene therapy using the intestine
AU6614596A (en) Inhibition of gene expression
AU3737297A (en) Bacteriophage-mediated gene therapy
IL122976A0 (en) Control of cd44 gene expression for therapeutic use
AU3891299A (en) Combination therapy for treatment of depression
GB9512290D0 (en) Uses of polyhexanide
AU6257298A (en) Breast cancer specific gene 1
AU3002497A (en) Treatment of human cancers with an adenovirus vector containing an interferon consensus gene
AU5300396A (en) Radiation enhanced gene therapy for treatment of tumors
AU6282896A (en) Gene therapy of solid tumors with interferons alone or with other immuno-effector proteins
AU6040296A (en) Methods of inducing bef-1 transcription factor
AU5750196A (en) Gene therapy of hepatocellular carcinoma through cancer-specific gene expression
AU4862396A (en) Human obesity gene
AU6821196A (en) Transdermal administration of vorozole
AU2548095A (en) Human inhibitor of apoptosis gene 1
AU4941096A (en) Self-deleting vectors for gene therapy
AU4984696A (en) Capl-specific oligonucleotides and methods of inhibiting metastatic cancer
AU3628699A (en) Transcription factors regulating the expression of ethylene-inducible genes
AU5778399A (en) Gene therapy for treatment of cancer
AU7130696A (en) Combination of beta-interferon for the treatment of prostate cancer
AUPO633497A0 (en) Novel human tumour suppressor gene